Michael Makris/LinkedIn
Dec 18, 2025, 23:25
Michael Makris: Excellent Article in This Week’s NEJM Explains Word Estimand Clearly
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
“Do you know what is an “estimand”?
I had never heard of the word until today, but this excellent article in this week’s New England Journal of Medicine (NEJM) explains it clearly.
Essentially, it is the effect of actually taking a drug in a randomised trial. Although simplistically attractive there are good reasons why Intention to Treat (ITT) analysis should remain the gold standard. I can see estimands being used increasingly by manufacturers and sponsored speakers at meetings.”
Discover the latest in Hemostasis Today.
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026
-
Jul 12, 2026, 06:45Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026